NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Johnson & Johnson JNJ
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY18 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$94.2B
▲ 6.0% vs FY2024
Dividend streak
18 yrs
Raised every year since 2008
EPS · FY25
$11.03
Dividend / sh · FY25
$5.14
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
28.5%
Dividend coverage
2.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 94.2B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
28 cents of every revenue dollar became profit this year.
Per share
USD 11.03
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 2.1 times — the rest stayed in the company.
Profitability
—
Return on equity, FY2025
ROE
Operating margin34.6%
Net margin28.5%
Return on assets14.1%
Returned to shareholders
USD 6.0B
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 6.0B
Share of profit22.2%
Consecutive raises18 years
USD 6.0B in buybacks — 22% of the year's profit went back to shareholders.
Growth
+2.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.6%
+2.7%
+3.0%
+2.9%
Net income
+14.3%
+12.7%
+5.7%
+4.8%
EPS, diluted
+17.9%
+14.9%
+7.2%
+5.7%
Dividend / share
+4.9%
+5.2%
+5.7%
+6.1%
Returned to shareholders
−0.5%
+13.1%
+1.2%
+9.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 199.2B
total assets, end of FY2025
Total assetsUSD 199.2B
CashUSD 19.7B
Gross debtUSD 41.4B
Net debtUSD 21.7B
Current ratio1.03×
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
94.2
88.8
85.2
80.0
78.7
82.6
82.1
81.6
76.5
71.9
70.1
74.3
71.3
67.2
65.0
61.6
61.9
63.7
61.1
Operating income $B
32.6
16.7
15.1
19.4
19.2
16.5
17.3
·
·
·
·
21.6
16.4
15.0
13.8
17.7
16.6
·
·
EBITDA $B
40.1
24.0
22.5
26.3
26.6
23.7
24.3
·
·
·
·
25.5
20.5
18.6
16.9
20.6
19.4
·
·
Income tax $B
5.8
2.6
1.7
3.0
1.4
1.8
2.2
2.7
16.4
3.3
3.8
4.2
1.6
3.3
2.7
3.6
3.5
4.0
2.7
Net income $B
26.8
14.1
35.2
17.9
20.9
14.7
15.1
15.3
1.3
16.5
15.4
16.3
13.8
10.9
9.7
13.3
12.3
12.9
10.6
EPS, diluted $
11.03
5.79
13.72
6.73
7.81
5.51
5.63
5.61
0.47
5.93
5.48
5.70
4.81
3.86
3.49
4.78
4.40
4.57
3.63
Dividend / sh $
5.14
4.91
4.70
4.45
4.19
3.98
3.75
3.54
3.32
3.15
2.95
2.76
2.59
2.40
2.25
2.11
1.93
1.79
1.62
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
74 of 74
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed